Short answer
ENANTA PHARMACEUTICALS INC (ENTA) filed an 8-K current report with the SEC on June 18, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Exhibits 99.1 and 99.2 furnished under Regulation FD, likely containing the substantive investor disclosure.
ENANTA PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Exhibits 99.1 and 99.2 furnished under Regulation FD, likely containing the substantive investor disclosure
- Disclosure not deemed filed under Exchange Act Section 18, limiting related liability exposure
- Exhibits excluded from incorporation into other SEC filings unless specifically referenced
Item EX-99.1 · Exhibit EX-99.2
- FDA End-of-Phase 2 agreement advances zelicapavir into registrational Phase 2b/3 adult RSV trial in 4Q 2026
- Adult Phase 2b targets minimum 200 high-risk patients, with topline data expected in 2027
- Pediatric Phase 2b planned for 3Q 2026 in approximately 150 patients aged 28 days to 36 months
- Prior high-risk adult study showed 6.7-day symptom-resolution benefit and hospitalization rates of 5% placebo versus 0% zelicapavir
- Potential global market exceeds $2 billion, with over 3 million U.S. patients addressable without an available RSV treatment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ENANTA PHARMACEUTICALS INC 8-K filings
Get the next ENTA 8-K as it lands
Follow ENTA for push alerts, or ask the research agent what this filing means.